You are viewing an expired study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Davis, California 95616

  • Drug Hypersensitivity

Purpose:

The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable.


Criteria:

Inclusion Criteria: - Agreed to avoid disallowed meds Exclusion Criteria: - Known hypersensitivity to hyaluronidase and/or bee sting - Previous known exposure to ovine hyaluronidase or bovine hyaluronidase - Atopic individuals assessed by medical history - Topical/inhaled/systemic corticosteroids within 30 days - Concurrent use of antihistamines or anti-inflammatory during study - Active or chronic disease likely to affect immune function - History of alcohol/drug abuse within 6 months


NCT ID:

NCT00198458


Primary Contact:

Study Director
Lisa R Grillone, PhD
ISTA Pharmaceuticals, Inc.


Backup Contact:

N/A


Location Contact:

Davis, California 95616
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.